The American Journal of Medicine
Volume 120, Issue 8 , Pages 685-692 , August 2007

Impact of Acute Beta-Blocker Therapy for Patients with Non–ST-Segment Elevation Myocardial Infarction

  • Chadwick D. Miller, MD

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • Matthew T. Roe, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Jyotsna Mulgund, MS

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • James W. Hoekstra, MD

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • Renato Santos, MD

      Affiliations

    • Wake Forest University Health Sciences, Winston-Salem, NC
    • ,
  • Charles V. Pollack Jr., MD, MA

      Affiliations

    • Pennsylvania Hospital, University of Pennsylvania School of Medicine, Philadelphia
    • ,
  • E. Magnus Ohman, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • W. Brian Gibler, MD

      Affiliations

    • University of Cincinnati College of Medicine, Cincinnati, Ohio.
    • ,
  • Eric D. Peterson, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationRequests for reprints should be addressed to Eric Peterson, MD, MPH, Duke Clinical Research Institute, 2400 Pratt Street, Room 7009, Durham, NC 27705.

  • Image Result

    Adjusted risk of in-hospital clinical outcomes by acute beta-blocker use. Patients in the congestive heart failure (CHF) group had signs of CHF upon hospital presentation.

    Adjusted risk of in-hospital clinical outcomes by acute beta-blocker use. Patients in the congestive heart failure (CHF) group had signs of CHF upon hospital presentation.

  • Image Result

    Adjusted risk of in-hospital mortality among propensity groups. Patients were categorized into 6 equal groups based upon the propensity to receive acute beta-blockers ranging from those with the lowes

    Adjusted risk of in-hospital mortality among propensity groups. Patients were categorized into 6 equal groups based upon the propensity to receive acute beta-blockers ranging from those with the lowest propensity (Group 1, 66.5%) to those with the highest propensity (Group 6, 92.4%).

 CRUSADE is funded by the Schering-Plough Corporation. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership provides additional funding support. Millennium Pharmaceuticals, Inc. also funded this work.

PII: S0002-9343(07)00413-5

doi: 10.1016/j.amjmed.2007.04.016

The American Journal of Medicine
Volume 120, Issue 8 , Pages 685-692 , August 2007

Article Tools

* Image Usage & Resolution